Business Context and Reporting Period
This Form 8-K filing by Trevi Therapeutics, Inc. (TRVI) reports a material corporate event dated August 14, 2025. The filing addresses the departure of a senior executive and the interim appointment of a replacement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Lisa Delfini resigned as Chief Financial Officer, with her employment ending on August 22, 2025.
- Reason for Departure: The resignation is not the result of any disagreement with the Company regarding operations, policies, or practices.
- Interim Appointment: Jennifer L. Good, President and Chief Executive Officer, will serve as the interim principal financial officer until a permanent replacement is designated.
Guidance, Outlook, and Contingencies
The filing contains no financial guidance, outlook, or management commentary on future business prospects. Regarding contingencies, Ms. Delfini's separation benefits are subject to the execution of a severance and release of claims agreement. This agreement includes a general release of claims, a non-disparagement clause, and reaffirmation of confidentiality, non-solicitation, and non-compete obligations.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (August 22, 2025).
- Verify the terms of the Executive Separation Benefits and Retention Plan applicable to Ms. Delfini.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Review the referenced Proxy Statement on Schedule 14A (filed April 29, 2025) for biographical details on the interim CFO, Jennifer L. Good.